The DOI matches its Crossref record.
A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Abstract
BACKGROUND: Low-molecular-weight heparins (LMWHs) are now standard therapy for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). No published trials have compared LMWHs, and few studies have examined outpatient therapy for PE. Only tinzaparin sodium has demonstrated superiority to unfractionated heparin in a clinical trial. METHODS: We compared 2 LMWH products, tinzaparin and dalteparin sodium, for the treatment of acute DVT and PE in a randomized, controlled clinical trial of consecutive outpatients presenting to a venous thromboembolism service at 4 tertiary-care hospitals. Patients were treated with subcutaneous tinzaparin sodium, 175 IU/kg every 24 hours, or subcutaneous dalteparin sodium, 200 IU/kg every 24 hours, for at least 5 days. Warfarin sodium therapy was started simultaneously and continued for 90 days. The primary end point was efficacy (recurrence of venous thromboembolism); safety (bleeding) was a composite end point. RESULTS: Two hundred fifty-four patients received tinzaparin (39 with PE and 215 with DVT) and 251 received dalteparin (51 with PE and 200 with DVT). Most patients had an active malignancy or idiopathic DVT/PE. The outcome events occurred in 11 (4.4%; 95% confidence interval [CI], 2.2%-7.7%) and 15 patients (5.9%; 95% CI, 3.3%-9.5%) in the dalteparin and tinzaparin groups, respectively, including 9 and 10 recurrences, respectively, and 2 and 5 major hemorrhages, respectively (P = .44). The 95% CI on the difference of -1.5% was -5.3% to 2.4%. CONCLUSIONS: Tinzaparin and dalteparin are safe and effective for the outpatient treatment of DVT or PE. Our finding of no differences between the LMWHs based on major clinical end points means that practical issues can be the deciding factor on which drug to use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jaff, M. R., McMurtry, M. S., Archer, S. L., Cushman, M., Goldenberg, N., Goldhaber, S. Z., Jenkins, J. S., Kline, J. A., Michaels, A. D., Thistlethwaite, P., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214914f · Cited by 2,229
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Derivation and validation of a prognostic model for pulmonary embolism
Aujesky, D., Obrosky, D. S., Stone, R. A., Auble, T. E., Perrier, A., Cornuz, J., Roy, P.-M., & Fine, M. J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200506-862oc · Cited by 1,303
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
Laporte, S., Mismetti, P., Décousus, H., Uresandi, F., Otero, R., Lobo, J. L., Monreal, M., & the RIETE Investigators (2008) · Circulation · doi:10.1161/circulationaha.107.726232 · Cited by 671
Aujesky, D., Roy, P.-M., Verschuren, F., Righini, M., Osterwalder, J., Egloff, M., Renaud, B., Verhamme, P., Stone, R. A., Legall, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60824-6 · Cited by 598
Carrier, M., Le Gal, G., Wells, P. S., & Rodger, M. A. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-9-201005040-00008 · Cited by 473
Self-citationAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub4 · Cited by 428
Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study
ZONDAG, W., MOS, I. C. M., CREEMERS‐SCHILD, D., HOOGERBRUGGE, A. D. M., DEKKERS, O. M., DOLSMA, J., EIJSVOGEL, M., FABER, L. M., HOFSTEE, H. M. A., HOVENS, M. M. C., et al. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04388.x · Cited by 382
Gal, G., Fine, M. J., Roy, P.-M., Sanchez, O., Verschuren, F., Cornuz, J., Meyer, G., Perrier, A., Righini, M., Aujesky, D., et al. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-05-0285 · Cited by 358
Validation of a model to predict adverse outcomes in patients with pulmonary embolism
Aujesky, D., Roy, P.-M., Le Manach, C. P., Verschuren, F., Meyer, G., Obrosky, D. S., Stone, R. A., Cornuz, J., & Fine, M. J. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi588 · Cited by 274
Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis
Zondag, W., Kooiman, J., Klok, F. A., Dekkers, O. M., & Huisman, M. V. (2013) · European Respiratory Journal · doi:10.1183/09031936.00093712 · Cited by 168
Otero, R., Trujillo-Santos, J., Cayuela, A., Rodríguez, C., Barron, M., Martín, J. J., & Monreal, M. (2007) · European Respiratory Journal · doi:10.1183/09031936.00071007 · Cited by 74
Metadata
- Authors
- Wells, P. S., Anderson, D. R., Rodger, M. A., Forgie, M. A., Florack, P., Touchie, D., Morrow, B., Gray, L., O’Rourke, K., Wells, G., Kovacs, J., & Kovacs, M. J.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2005-04-11
- Volume
- 165
- Issue
- 7
- Pages
- 733
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2137730697
- Cited by
- 174
- References
- 0
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.